Savior Lifetec

Savior Lifetec EBIT per Share

The EBIT per Share of Savior Lifetec (4167.TWO) as of Oct 26, 2026 is 0.60 TWD. In the previous year, EBIT per Share was 0.37 TWD — a change of 59.69% (higher).

EBIT per Share

0.60TWD

YoY

59.69%

Last updated:

EBIT per Share of Savior Lifetec is 2025 0.60 TWD. EBIT per Share of Savior Lifetec was 2024 0.37 TWD. It decreases by 59.69% higher compared to the previous year.

The Savior Lifetec EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2024
0.37 TWD
Jan 1, 2025
0.60 TWD
Jan 1, 2026 (e)
0.42 TWD
Jan 1, 2027 (e)
0.35 TWD
Jan 1, 2028 (e)
-0.08 TWD
Jan 1, 2029 (e)
1.01 TWD
Jan 1, 2030 (e)
0.13 TWD
Jan 1, 2031 (e)
1.24 TWD
The Savior Lifetec EBIT per Share history
YEAREBIT per ShareYoY
est1.24TWD+828.40%
est0.13TWD-86.74%
est1.01TWD-1,408.14%
est-0.08TWD-122.09%
est0.35TWD-16.68%
est0.42TWD-30.10%
0.60TWD+59.69%
0.37TWD-5,232.38%
-0.01TWD-104.45%
0.16TWD+89.60%
0.09TWD-90.47%
0.91TWD+450.44%
0.16TWD-112.34%
-1.34TWD-785.74%
0.19TWD-129.31%
-0.66TWD-70.73%
-2.27TWD+26.78%
-1.79TWD+42.17%
-1.26TWD-58.73%
-3.05TWD+36.71%
-2.23TWD+75.38%
-1.27TWD-38.85%
-2.08TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

EBIT per Share of Savior Lifetec is 0.60 TWD in 2025.

EBIT per Share of Savior Lifetec changed from 0.37 TWD to 0.60 TWD, representing a 59.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Savior Lifetec

All Key Metrics — Savior Lifetec